Section Arrow
Quote
BTAI.NASDAQ
- BioXcel Therapeutics Inc
Quotes are at least 15-min delayed:2026/07/06 16:56 EDT
After Hours
Last
 1.1399
+0.0399 (+3.63%)
Bid
1.12
Ask
1.14
High 1.18 
Low 1.1 
Volume 33.49K 
Regular Hours (Closed)
Last
 1.1
-0.28 (-20.29%)
Day High 
1.35 
Prev. Close
1.38 
1-M High
1.4588 
Volume 
4.05M 
Bid
1.12
Ask
1.14
Day Low
1.1 
Open
1.35 
1-M Low
1.05 
Market Cap 
42.61M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.32 
20-SMA 1.23 
50-SMA 1.2 
52-W High 8.08 
52-W Low 1.01 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.77/-1.29
Enterprise Value
127.27M
Balance Sheet
Book Value Per Share
-3.42
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
642.00K
Operating Revenue Per Share
0.03
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health38.28+1.48+4.02%-- 
After Hours 38.2091 -0.0709 -0.19%
VTRSViatris16.8+0.1+0.60%-- 
After Hours 16.84 +0.04 +0.24%
HLNHaleon plc9.72-0.1-1.02%19.9PE
After Hours 9.72 0 0.00%
ESPREsperion Therapeutics3.15-0.01-0.32%-- 
After Hours 3.16 +0.01 +0.32%
ZTSZOETIS75.42+0.62+0.83%12.26PE
After Hours 75.41 -0.01 -0.01%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.